 |
|
Home | ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe |
 |
ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe
|
 |
- March 04, 2011
-
ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe Mar. 4, 2011 (PR Newswire) — PARIS and LONDON, March 4, 2011 /PRNewswire-FirstCall/ — Bristol-Myers Squibb Company (http://www.bms.com)(NYSE: BMY) and AstraZeneca (http://www.astrazeneca.com) (NYSE: AZN)today announced that the European Commission has approved a label update for ONGLYZA(R) (saxagliptin) in the treatment of adults with type [...]This article (ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe) was originally developed by and is property of American Banking News. Checkout American Banking News for up-to-date banking news and peer to peer lending news.
- Read more at:http://www.americanbankingnews.com/2011/03/04/onglyzar-becomes-the-first-dpp-4-inhibitor-available-for-use-in-europe/
|
 |
|
 |
|
 |
